Introduction and Aim: The purpose of replacement therapy in adrenal insufficiency (AI) is mimicking endogenous cortisol levels as closely as possible: dual release hydrocortisone (DR-HC) has been introduced to replicate the circadian cortisol rhythm. Multiple daily saliva collections could be used to assess the cortisol rhythm during real life: our aim was to study the salivary cortisol profile in AI. Materials and Methods: We prospectively evaluated, in an observational study, 18 adult outpatients with AI (11 primary and 7 secondary AI), switched from conventional treatment (conv-HC, 25 mg/day) to the same dose of DR-HC. We collected six samples of saliva in a day, measuring cortisol (F) and cortisone (E) with LC-MS/MS. Forty-three matche...
Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulnes...
Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulnes...
Context Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an...
The purpose of replacement therapy in Adrenal Insufficiency (AI) is mimicking endogenous cortisol le...
Context: Cortisol has a distinct circadian rhythm regulated by the brain's central pacemaker. Loss o...
The appreciation of the unacceptable outcomes of patients with adrenal insufficiency has brought new...
Introduction Adrenal Insufficiency (AI), especially iatrogenic-AI, is a treatable cause of mortality...
Context:Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate...
Background Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with divers...
Objective: Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and...
Context: Cortisol has a distinct circadian rhythm regulated by the brain's central pacemaker. Loss o...
Objective: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy was developed to ...
Objective: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy was developed to ...
Adrenal insufficiency (AI) is associated with increased cardiovascular morbidity and mortality and r...
Adrenal insufficiency (AI) is associated with increased cardiovascular morbidity and mortality and r...
Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulnes...
Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulnes...
Context Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an...
The purpose of replacement therapy in Adrenal Insufficiency (AI) is mimicking endogenous cortisol le...
Context: Cortisol has a distinct circadian rhythm regulated by the brain's central pacemaker. Loss o...
The appreciation of the unacceptable outcomes of patients with adrenal insufficiency has brought new...
Introduction Adrenal Insufficiency (AI), especially iatrogenic-AI, is a treatable cause of mortality...
Context:Patients with treated adrenal insufficiency (AI) have increased morbidity and mortality rate...
Background Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with divers...
Objective: Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and...
Context: Cortisol has a distinct circadian rhythm regulated by the brain's central pacemaker. Loss o...
Objective: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy was developed to ...
Objective: Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy was developed to ...
Adrenal insufficiency (AI) is associated with increased cardiovascular morbidity and mortality and r...
Adrenal insufficiency (AI) is associated with increased cardiovascular morbidity and mortality and r...
Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulnes...
Measuring salivary cortisol is both convenient and non-invasive for patients; however, its usefulnes...
Context Oral once-daily dual-release hydrocortisone (DR-HC) replacement therapy has demonstrated an...